Jie Wang

机构：Roswell Park Comprehensive Cancer Center, Shenzhen University, Xiamen University, Chinese Academy of Medical Sciences & Peking Union Medical College, First Affiliated Hospital of Xiamen University, National Cancer Center, Dana-Farber Cancer Institute, Institute of Vegetables and Flowers, Chinese Academy of Agricultural Sciences · ORCID：0000-0002-3432-8085

发表论文 82 篇 · 总被引 3117 次 · h-index 24

代表论文

• Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors (2022 · European Journal of Medicinal Chemistry · 被引 27)
• ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC). (2024 · Journal of Clinical Oncology · 被引 24)
• KIF15 is essential for USP10-mediated PGK1 deubiquitination during the glycolysis of pancreatic cancer (2023 · Cell Death and Disease · 被引 24)
• Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 16)
• Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial (2025 · The Lancet Respiratory Medicine · 被引 10)
• Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R/T790M/C797S inhibitors (2024 · European Journal of Medicinal Chemistry · 被引 9)